Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAVE ranibizumab regimen study in neovascular age-related macular degeneration
2011-004959-39Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Novartis. Primary endpoint: Average visual acuity change from Month 3 to Month 4 through Month 12. Started Feb 2013; status: terminated.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2011-004959-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004959-39.